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The term Exosome has come into use to define nano-
vesicles contained in multivesicular endosomes (MVE), 
secreted by fusion of MVE with the plasma membrane (1-3). 
Exosomes are secreted in vivo by almost any cell type and 
can be isolated from body fluids (4-6). Indeed, circulating 
vesicles account for both exosomes and microvesicles (MVs), 
which can be purified by various purification methods and 
fully discriminated according to their shape, size and CD-
markers (7,8). Due to their protein and RNA content, 
once internalized, exosomes have the potential to act as 
“translational” organelles, altering the expression pattern of 
recipient cells, their growth, and fate. In fact, exosomes are 
involved in many of physio-pathological processes, thereby 
including cancer (9).
The work recently published by Franzen et al. in The 
Journal of Urology (10) examined  the role of exosomes 
in intercellular communication and their potential as 
noninvasive cancer biomarker source to assess disease and its 
progression, or vehicles for therapeutic delivery in urologic 
cancer (11). The need for a predictor of malignancy is 
universally recognized. This is particularly true in the case of 
early tumors. There is evidence that cancer-derived exosomes 
contribute to tumor progression and metastasis (12). Tumor 
cells produce exosomes, emerging as a potential for the early 
detection or therapy of human cancer (13).
Human urinary exosomal proteome has been extensively 
studied (7). Urinary exosomes come from every cell type 
of the urinary tract, kidney and prostate (14-16). There 
is increasing interest in urinary exosomes, due to their 
ability to carry information specific of the tissue of origin. 
I am positive about the idea that exosomes, which can be 
easily isolated from human urine by minimally invasive 
techniques, can allow to detect biomarkers in patients 
with urogenital cancer, with a wealth of applications in 
therapy and diagnosis, as we have already observed (17). 
Bladder cancer is one example, as it represents a serious 
health problem, (about 8% of all human malignancies), still 
burdened by a high percentage of relapse (18).
However, I am sceptic to the idea that exosomes can 
be used in therapeutics as RNA or therapy delivery vector 
to target cancer cells. Surely, RNA would be protected by 
the membrane from degradation. Nevertheless, it seems 
that we still know too little about the surface proteins of 
exosomes. We have shown that among the exosomal surface 
proteins there are the respiratory chains and F1Fo-ATP 
synthase, conducting an oxidative phosphorylation (19,20). 
Before seeing the contents of a package, its envelope 
must be opened. Similarly, before the RNA content of 
an exosome complex is shed, and it can affect the cell 
expression pattern, its surface proteins will have interacted 
with the cytosol. We have reported the proteome analysis of 
urinary exosomes, studied by Orbitrap mass spectrometry, 
compared to urinoma (20). Cytoscape software analysis 
of the data elucidated the enriched presence in urinary 
exosomes of proteins clustered to aerobic metabolism. 
Moreover, functional experiments showed that urinary 
exosomes carry out oxidative phosphorylation. The same 
applies to exosomes derived from human umbilical cord 
mesenchymal cells (MSC), which are able to conduct an 
aerobic metabolism (19). Such emerging metabolic function 
for both human MSC and urinary exosomes should not be 
ignored. It appears consistent with the report that exosomes 
can transfer the aerobic metabolism capacity to profoundly 
hypo-metabolic cells in less than one hour (21). This 
dramatic effect overturned the fate of doomed cells long 
before any transcriptional event can have occurred. In case 
of tumor cells, this may not be desirable. For example it 
was found that various concentrations of exosomes purified 
from the supernatants of human bladder cancer T24 cell 
cultures induce the proliferation and decrease the rates of 
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apoptosis (22). Having the observations been limited 
to late events, posing ATP availability as a prerequisite 
(viability assay of at 72 hr, Annexin V and transcription 
factors activity), an involvement of early metabolic effect 
cannot be excluded. In fact, it was also found that bladder 
cancer exosomes can cause urothelial cells to undergo 
epithelial-mesenchymal transition (EMT). Authors treated 
primary urothelial cells with the exosomes isolated mRNA 
and evaluated the expression of several mesenchymal 
genes necessarily after a 4- and 6-h time to reveal newly 
transcribed mRNAs (23). While it is known that the EMT 
induces invasive properties in epithelial tumors, very little is 
known about EMT-induced metabolic changes. A study on 
HER2-positive BT-474 breast cancer cells showed enhanced 
aerobic metabolism, along with the overexpression of 
specific glucose transporters (24).
A method to be used clinically should be simple, cost-
effective and minimally invasive, which exosome collection 
from urine appears to be. In conclusion, I am optimistic 
that further studies about the potential for exosomes will 
help in diagnosis, treatment and prognosis assessment of 
urinary tract cancer. However, several unanswered questions 
regarding the metabolic potential of exosomes remain. In 
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